FDA to expedite ev3's Pipeline
June 21, 2010 by MassDevice staff
The Food & Drug Administration grants ev3 Inc. an expedited review of the pre-market approval application the company filed in May for its Pipeline cerebral aneurysm treatment.
One of Covidien plc's (NYSE:COV) pending acquisitions won some good news from the Food & Drug Administration after it granted ev3 Inc. (NSDQ:EVVV) an expedited review of its Pipeline embolization treatment for cerebral aneurysms.
Plymouth, Minn.-based ev3 said the FDA agreed to consider the pre-market approval application it filed May 18 for the device, which is designed to treat large, giant and wide-necked brain aneurysms. The federal watchdog agency granted the company an expedited review and processing of the PMA.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
- Raising an early warning in the ICU: T3
- Staff shakeup underway at Russian medical device regulator
Navigation
NEWS
Covidien restates Q2 financials ahead of pharma spinout | Wall Street Beat
Covidien restates its financial results for its fiscal 2nd quarter ahead of the spinout of its...
Can the FDA keep its user fee promises amid sequester?
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
Weight loss: EnteroMedics plans on Q1 PMA submission for Maestro device
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical's Q1 profits soar 1000%
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
Supreme Court to hear Medtronic's appeal of Boston Scientific's CRM patent win
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
